PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status

Stéphane Supiot; Helen Zhao; Klas Wiman; Richard P. Hill; Robert G. Bristow

doi:10.1016/j.radonc.2008.01.001

PRIMA-1^met radiosensitizes prostate cancer cells independent of their MTp53-status

Stéphane Supiot
, Helen Zhao
, Klas Wiman
, Richard P. Hill
, Robert G. Bristow^*

^*Corresponding author for this work

Division of Cancer Sciences (L5)

University Health Network
University of Toronto
Karolinska University Hospital
Radiation Oncology and Medical Biophysics

Research output: Contribution to journal › Article › peer-review

Abstract

The novel agent PRIMA-1^met can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1^met as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1^met may therefore act independently of MTp53 status and WTp53 transactivation.

Original language	English
Pages (from-to)	407-411
Number of pages	5
Journal	Radiotherapy and Oncology
Volume	86
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2008.01.001
Publication status	Published - Mar 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hypoxia
p53
PRIMA-1
Prostate cancer
Radiosensitizer

Research Highlights, Institutes and Platforms

Manchester Cancer Research Centre

Access to Document

10.1016/j.radonc.2008.01.001

Cite this

@article{2ecfd236da204b07b05ca925092ce585,

title = "PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status",

abstract = "The novel agent PRIMA-1met can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1met as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1met may therefore act independently of MTp53 status and WTp53 transactivation.",

keywords = "Hypoxia, p53, PRIMA-1, Prostate cancer, Radiosensitizer",

author = "St{\'e}phane Supiot and Helen Zhao and Klas Wiman and Hill, \{Richard P.\} and Bristow, \{Robert G.\}",

year = "2008",

month = mar,

doi = "10.1016/j.radonc.2008.01.001",

language = "English",

volume = "86",

pages = "407--411",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status

AU - Supiot, Stéphane

AU - Zhao, Helen

AU - Wiman, Klas

AU - Hill, Richard P.

AU - Bristow, Robert G.

PY - 2008/3

Y1 - 2008/3

N2 - The novel agent PRIMA-1met can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1met as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1met may therefore act independently of MTp53 status and WTp53 transactivation.

AB - The novel agent PRIMA-1met can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1met as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1met may therefore act independently of MTp53 status and WTp53 transactivation.

KW - Hypoxia

KW - p53

KW - PRIMA-1

KW - Prostate cancer

KW - Radiosensitizer

UR - https://www.scopus.com/pages/publications/40249104606

U2 - 10.1016/j.radonc.2008.01.001

DO - 10.1016/j.radonc.2008.01.001

M3 - Article

C2 - 18237796

AN - SCOPUS:40249104606

SN - 0167-8140

VL - 86

SP - 407

EP - 411

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -